|Articles|January 10, 2017

endpoint Selected as IRT Provider for Ferring

Interactive Response Technology solutions company, endpoint, has been chosen as the sole IRT provider for Denmark-based Ferring Pharmaceuticals AS.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
September 10th 2025
Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Phase III EMPOWER-Lung 3 Trial Confirms Five-Year Survival Benefit With Libtayo Plus Chemotherapy in NSCLC
September 9th 2025
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
September 9th 2025
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
September 9th 2025

endpoint Selected as IRT Provider for Ferring

Newsletter

Related Articles

Trending on Applied Clinical Trials Online

Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial

AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer

eClinical Technology: Misconceptions, Challenges, and Opportunities

Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer

Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial